Dr. Julien Grogg will Lead the Company's Transition to Clinical Development Building on Promising Primate Study GENEVA, 30 January, 2025...

Release Tx Announces New CEO, aligning with the company’s recent pivot towards treating genetic disorders of the CNS without gene therapy

Release Therapeutics' strategic pivot towards treating genetic disorders of the central nervous system without gene therapy.

We are pleased to announce that, with the recent progress in the development of its unique platform technology, MaxiVAX is morphing into...